真实世界重度哮喘停用奥马珠单抗后疗效持续时间
该开放前瞻性研究纳入49例经奥马珠单抗治疗6年后自愿停药的重度哮喘患者,评估停药后反应持续性。结果提示60%患者停药后疗效至少持续4年。
要点
- 重度哮喘经奥马珠单抗治疗6年后停药,60%患者疗效至少持续4年。
- 真实世界数据支持部分患者可考虑停用奥马珠单抗。
核心结论
- 6年奥马珠单抗治疗后停药,60%患者疗效至少持续4年。
研究设计与样本
- 开放前瞻性研究,纳入49例经奥马珠单抗治疗6年后自愿停药的重度哮喘患者。
主要发现
- 随访13至48个月间7例患者复发。
关键数值与推荐
- 哮喘复发定义为任何重度哮喘急性发作并伴哮喘控制丧失。
临床怎么用
- 真实世界重度哮喘患者经6年奥马珠单抗治疗后,可评估停药可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration of the treatment remains unclear. In an open prospective study, we sought to assess the persistence of response in subjects withdrawing from omalizumab treatment. We evaluated 49 patients who voluntarily accepted to discontinue omalizumab treatment after 6 years of therapy. Asthma relapse was defined as any severe asthma exacerbation associated with loss of asthma control. Twelve patients relapsed in the first year of follow-up, and 7 within 13 and 48 months. These results suggest that the effects of 6 years of omalizumab may persist after discontinuation of therapy in 60% of patients for at least 4 years.
引用
- Vennera MDC, Sabadell C, Picado C, et al. Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma. Thorax. 2017. PMID: 29079610. doi:10.1136/thoraxjnl-2017-210017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。